In May 2013, GlaxoSmithKline (980 Great West Road, Brentford, Middlesex, TW8 9GS, UK) established a new online system to enable scientific researchers to request access to anonymised patient level clinical trial data. Providing access to individual patient data collected in clinical trials enables conduct of further research that may help advance medical science or improve patient care. In turn, this helps ensure that the data provided by research participants are used to maximum effect in the creation of new knowledge and understanding. However, when providing access to individual patient data, maintaining the privacy and confidentiality of research participants is critical. This article describes the approach we have taken to prepare data for sharing with other researchers in a way that minimises risk with respect to the privacy and confidentiality of research participants, ensures compliance with current data privacy legal requirements and yet retains utility of the anonymised datasets for research purposes. We recognise that there are different possible approaches and that broad consensus is needed.
[1]
Frank Rockhold,et al.
Access to patient-level data from GlaxoSmithKline clinical trials.
,
2013,
The New England journal of medicine.
[2]
P. Vallance,et al.
Secure use of individual patient data from clinical trials
,
2013,
The Lancet.
[3]
B. Fitzgerald.
Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule
,
2015
.
[4]
Psychological distress and death from cardiovascular disease
,
2012,
BMJ : British Medical Journal.
[5]
Fiona Godlee,et al.
Clinical trial data for all drugs in current use
,
2012,
BMJ : British Medical Journal.
[6]
D. Altman,et al.
Preparing raw clinical data for publication: guidance for journal editors, authors, and peer reviewers
,
2010,
BMJ : British Medical Journal.